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Abstract
Stably suppressed viremia during ART is essential for establishing reliable simian models for HIV/AIDS. We tested the efficacy
of a multidrug ART (highly intensified ART) in a wide range of viremic conditions (10
3–10
7 viral RNA copies/mL) in
SIVmac251-infected rhesus macaques, and its impact on the viral reservoir. Eleven macaques in the pre-AIDS stage of the
disease were treated with a multidrug combination (highly intensified ART) consisting of two nucleosidic/nucleotidic
reverse transcriptase inhibitors (emtricitabine and tenofovir), an integrase inhibitor (raltegravir), a protease inhibitor
(ritonavir-boosted darunavir) and the CCR5 blocker maraviroc. All animals stably displayed viral loads below the limit of
detection of the assay (i.e. ,40 RNA copies/mL) after starting highly intensified ART. By increasing the sensitivity of the assay
to 3 RNA copies/mL, viral load was still below the limit of detection in all subjects tested. Importantly, viral DNA resulted
below the assay detection limit (,2 copies of DNA/5*10
5 cells) in PBMCs and rectal biopsies of all animals at the end of the
follow-up, and in lymph node biopsies from the majority of the study subjects. Moreover, highly intensified ART decreased
central/transitional memory, effector memory and activated (HLA-DR
+) effector memory CD4
+ T-cells in vivo, in line with the
role of these subsets as the main cell subpopulations harbouring the virus. Finally, treatment with highly intensified ART at
viral load rebound following suspension of a previous anti-reservoir therapy eventually improved the spontaneous
containment of viral load following suspension of the second therapeutic cycle, thus leading to a persistent suppression of
viremia in the absence of ART. In conclusion, we show, for the first time, complete suppression of viral load by highly
intensified ART and a likely associated restriction of the viral reservoir in the macaque AIDS model, making it a useful
platform for testing potential cures for AIDS.
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Introduction
The study of persistence of viral sanctuaries during antiretro-
viral therapy (ART) and the possibility for their therapeutic
targeting is crucial for eradication of HIV-1. Animal models for
lentiviral persistence during therapy are therefore needed. The
creation of such animal models requires knowledge of the response
of animal lentiviruses to antiretroviral drugs adopted in treatment
of humans with HIV-1. Finding cross-active drugs has been a
difficult task because non-HIV-1 lentiviruses often mimic drug
resistance mutations found in HIV-1. This mimicry has been
shown for the viral protease [1] and for the portion of reverse
transcriptase (RT) that binds the non-nucleosidic reverse tran-
scriptase inhibitors (NNRTIs) [2].
One of the current models is based on macaques infected with a
molecularly engineered simian immunodeficiency virus (SIV-
mac239) expressing HIV-1 RT, in order to overcome drug
resistance mimicry of the primate lentiviruses to NNRTIs [3].
Another model (SIV-based) has been developed for neurotropic
infection, a condition often occurring in late-stage AIDS [4]. In
this case, in order to by-pass the different response to antiretro-
virals, the authors used a drug combination which is not adopted
in humans. However, in both of these animal models, low-level
viremia persisted and viral RNA was consistently detectable in
anatomical sanctuaries [3,4].
A model recently developed by our group is based on a
polyclonal virus, such as SIVmac251, mimicking, at least in part,
the genetic diversity of HIV-1 naturally inoculated in human
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combined ART consisting of two nucleosidic/nucleotidic reverse
transcriptase inhibitors (NRTIs), i.e. tenofovir and emtricitabine,
and the integrase inhibitor raltegravir [5,6]. In this treatment
model, the virus persists during ART, and viral load rebounds
following treatment suspension in a time frame remarkably similar
to that observed in humans after treatment interruption [7].
Recent research has added more credit to the macaque AIDS
model, showing that, similarly to humans [8,9], rhesus macaques
(Macaca mulatta) harbour a central memory CD4
+ T-cell reservoir,
which plays a pivotal role in AIDS pathogenesis [7,10]. Important
insight has been derived from comparisons between rhesus
macaques and sooty mangabays (Cercocebus atys) which, unlike M.
mulatta, do not progress to AIDS [11]. M. mulatta, but not C. atys,
shows up-regulation of the lentiviral co-receptor CCR5 in
activated central memory T-cells, thus rendering this T-cell pool
highly permissive to infection [10]. Conversely, the reduction of
the long-lived memory T-cells (CD95
+CD28
+), including central
memory T-cells, by the gold-based compound auranofin in
intensified ART (iART)-treated rhesus macaques resulted in
decreased levels of viral DNA and delayed progression of the
infection upon therapy suspension [7]. Therefore, a model
mimicking the effects of suppressive ART in humans is of
fundamental importance also for the study of the dynamics of this
viral reservoir.
One major limitation of current models for HIV persistence
during therapy is their large discrepancy from conditions observed
in humans. So far, due to financial and temporal constraints,
animals have been chosen from homogeneous cohorts in terms of
timing, type and route of the inocula, and have been treated in the
early phases of chronic infection [3–6] or during acute infection
[12]. Instead, at therapy initiation, HIV-infected humans are
usually characterized by different timings and routes of disease
acquisition and different levels of progression of the infection. In
order to obtain a robust animal model for HIV persistence during
therapy, the drug regimens should display similar efficacies as
compared to those employed for human treatment, and repro-
ducible control of heterogeneous viral loads in wide cohorts of
subjects with different characteristics and previous treatment
histories.
Here, we report a highly intensified ART (H-iART) regimen for
the simian model, reproducibly capable of decreasing viral load to
levels below assay detection limits in SIVmac251-infected
macaques starting from a wide range of baseline viremic
conditions, and overcoming previous treatment failures. We also
report an unexpectedly impressive restriction of viral DNA in
peripheral blood mononuclear cells, obtained by means of a
pharmacological strategy entirely based on antiretroviral drugs.
Materials and Methods
Cells and virological assays
CEMx174 and HTLV-I-transformed MT-4 cells were grown in
RPMI-1640 medium supplemented with glutamine (200 mg/mL)
(Invitrogen Life Technologies, Inc. Carlsbad, California), 10%
heat-inactivated fetal bovine serum (FBS; Invitrogen Life Tech-
nologies), penicillin (500 U/mL; Pharmacia Italia SPA) and
streptomycin (66.6 U/mL; Bristol-Myers, Sermoneta, LT).
Peripheral blood from uninfected nonhuman primates was
diluted 1:2 with PBS 1x-NaCl, and peripheral blood mononuclear
cells (PBMCs) were Ficoll-separated, resuspended at a concentra-
tion of 2610
6/mL and stimulated for 3 days with 5 mg/mL
phytohaemoagglutinin (PHA) (Difco Laboratories, Detroit, MI,
USA) and 100 units/mL of human recombinant IL-2 (Roche
Diagnostics, Indianapolis, IN, USA).
CEMx174, MT-4 cells, and three-day old PBMCs were
challenged with standard viral stock preparations for 2 hours in
an incubator at 37uC with 5% CO2, washed and incubated with
increasing drug concentrations (0.0001–1 mM), according to a
previously published protocol [5]. The assays on virus entry
inhibitors such as maraviroc (MRV), were conducted as in [13].
Briefly, the drug was first added during incubation with the virus
and the same drug concentrations were then re-added upon cell
washing. In MT-4 cells, through the MTT assay (MT4-MTT), we
measured inhibition of the cytopathic effect of the two viruses. The
assay was performed when the majority of control infected cells
were dead. At different intervals post-infection, the viral core
antigen p27 was measured in supernatants by antigen-capture
ELISA assays (Advanced BioScience lab., Inc.).
Animal treatment
The Indian rhesus macaques used in this study were housed at
Bioqual, Inc., according to standards and guidelines as set forth in
the Animal Welfare Act, the Guide for the Care and Use of
Laboratory Animals, and the Association for the Assessment and
Accreditation of Laboratory Animal Care (AAALAC), following
approval by the Institutional Animal Care and Use Committee
(IACUC). A total of eleven macaques have been enrolled for this
study, while five previously enrolled macaques have been
employed as historical controls.
For the pilot study, four SIVmac251-infected non-human
primates (M. mulatta) that had been stably viremic at least for the
last 3.3 months were put under a regimen (i.e. ART) consisting of
tenofovir (PMPA), emtricitabine (FTC) and raltegravir [5], for 1.5
months. To improve control of viral load, this regimen was
intensified by the addition of darunavir (DRV) boosted with
ritonavir (/r) [intensified ART (iART)]. After 80 days, the
treatment was further reinforced [highly intensified ART (H-
iART)] by the addition of maraviroc.
For the second part of the study, eight additional SIVmac251
infected animals were used. These animals were divided into three
treatment groups. One group (n=2) was treated with MRV/r
Author Summary
Novel research aimed at finding a cure for AIDS requires
animal models responding to human antiretroviral drugs.
However, there have been few antiretrovirals cross-active
against the simian viruses. In this study, we expanded the
arsenal of drugs active against the simian retrovirus
SIVmac251 and showed that this virus is inhibited by the
protease inhibitor, darunavir, and the CCR5 blocker,
maraviroc. Administration of these two drugs in combina-
tion with the reverse transcriptase inhibitors, tenofovir and
emtricitabine, and the integrase inhibitor, raltegravir,
resulted in prolonged plasma viral loads below assay
detection limits, and, surprisingly, restricted the viral
reservoir, a marker of which is viral DNA. We then decided
to employ this multidrug regimen (termed ‘‘highly
intensified ART’’) in order to increase the potency of a
previous strategy based on the gold drug auranofin, which
recently proved able to restrict the viral reservoir in vivo.A
short course of highly intensified ART following the
previous treatment resulted, upon therapy suspension, in
a remarkably spontaneous control of the infection, that
may pave the way to a persistent suppression of viremia in
the absence of ART. These results corroborate the
robustness of the macaque AIDS model as a vanguard
for potentially future treatments for HIV in humans.
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emtricitabine/raltegravir/DRV. A second group (n=4) was
treated with all H-iART drugs administered simultaneously. A
third group (n=2) was treated with iART to serve as controls.
For the combined antireservoir/antiretroviral therapeutic pro-
tocols, macaque P252, previously treated with iART plus the anti-
reservoir drug auranofin (for detail, see Ref. 7), was put under a H-
iART regimen for one month when viral load rebounded after
suspension of the previous treatment. Another macaque, P177 of
the pilot study, was treated (after the end of the follow-up aimed at
monitoring the effects of H-iART alone) with auranofin in
addition to H-iART. This macaque was then subjected, similarly
to P252, to a further cycle of H-iART at viral load rebound.
More detailed information on the macaques enrolled, their viro-
immunological background and the therapeutic regimens adopted
for each animal can be found in Table S1.
All animals were dosed subcutaneously with tenofovir, and
emtricitabine, and orally (with food) with raltegravir, DRV/r, and
MRV. Initial drug dosages were: tenofovir, 30 mg/kg/day;
emtricitabine, 50 mg/kg/day; raltegravir, 100 mg bid; DRV,
375 mg bid (for macaques starting from viral loads lower than 10
5
viral RNA copies/mL) or 700 mg bid (for macaques starting from
viral loads higher than 10
5 viral RNA copies/mL); ritonavir 50 mg
bid; MRV 100 mg bid.
Tenofovir and emtricitabine were kindly provided by Gilead
Sciences (Foster City, CA). Raltegravir, DRV/r and MRV were
purchased from the manufacturers.
Quantitative assay for SIVmac251 viral RNA levels
For measurement of plasma SIVmac251 RNA levels, a
quantitative TaqMan RNA reverse transcription-PCR (RT-
PCR) assay (Applied Biosystems, Foster City, Calif.) was used,
which targets a conserved region of the gag transcripts. The
samples were then amplified according to a method previously
validated in our hands [see ref 5 and Fig. S1]. The sensitivity of the
method is two copies per run, which results in a detection limit as
low as 40 RNA copies/mL in our routine analyses. Briefly, a 500-
mL aliquot of plasma was spun down at 13,0006 g for 1 h. The
liquid was poured off and 1 mL of RNA-STAT 60 was added.
After 5 min., 250 mL of chloroform was added and vortexed. The
samples were spun at the same speed for 1 h. The clear aqueous
layer on top was removed, and added to 500 mL of isopropanol.
Then, 10 mlo f1 0 mg/mL tRNA was added and precipitated
overnight at 220uC. The samples were spun for 1 hour, washed
with a cold (220uC) 75% ethanol solution, and re-spun for 1 h.
The RNA was resuspended in 30 mL of RNAse-free water. 10% of
the resuspended RNA was added to Taqman reagents (Applied
Biosystems), plus primers and probe, and amplified in a 7700
Sequence Detection System by Applied Biosystems. Briefly, the
sample was reverse transcribed at 48uC for 30 min. using One-
Step RT-PCR Master Mix (Applied Biosystems), then held at
95uC for 10 min., and run for 40 cycles at 95uC for 15 sec. and
60uC for 1 min. The following PCR primer/probes were used:
SIV2-U 59 AGTATGGGCAGCAAATGAAT 39 (forward prim-
er), SIV2-D 59 GGCACTATTGGAGCTAAGAC 39 (reverse
primer), SIV-P 6FAM-AGATTTGGATTAGCAGAAAGC-
CTGTTGGA-TAMRA (TaqMan probe). The signal was finally
compared to a standard curve of known concentrations from 10
7
down to 1 copy (the linear range of concentration/signal relation
spans eight Logs). All samples were done in triplicate for
consistency and accuracy. In our increased sensitivity analyses,
RNA was extracted from 6 mL of starting plasma, leading to a
sensitivity threshold of 3 copies/mL. The inter-assay variability of
the assay is 23.4%; The intra-assay variability is 20.6%.
Quantitative assay for SIVmac251 proviral DNA
For proviral DNA detection, cells were spun down to a pellet,
and the supernatant was poured off. The cell pellet was lysed with
1 mL of DNASTAT for 10 min. 250 mL of chloroform was added
and the mixture was vortexed. The samples were spun at 13,000
for 1 h. and the aqueous layer was removed and added to another
tube. To this, 500 mL of isopropanol was added, and the mixture
was precipitated overnight at 220uC. The samples were then spun
for 1 h and the precipitate was washed with a 220uC-cold, 75%
ethanol solution, and re-spun for 1 h. The DNA pellet was
resuspended in 30 mL of water and 10% of the resulting solution
was added to Taqman reagents (Applied Biosystems) plus primers
and probe (the same as in previous paragraph) and amplified in a
7700 Sequence Detection System by Applied Biosystems. The
signal was finally compared to a standard curve of known
concentrations from 10
6 down to 1 copy (the linear range of
concentration/signal relation spans seven Logs). The detection
limit of this assay is two copies of proviral DNA/5610
5 cells. The
inter-assay variability is 28.3%; the intra-assay variability is 9.9%.
The presence of PCR inhibitors in both the quantitative assays
(viral RNA and proviral DNA) has been ruled out by spiking the
samples with known amounts of viral RNA and proviral DNA
respectively (see Table 1 and Table S2).
Drug concentrations in plasma (DRV and MRV)
Animals were bled before feeding in the morning, in order to
obtain reliable measurements of trough drug levels. Plasma was
obtained from supernatants of ficoll-centrifuged blood.
For DRV, sample preparation involved addition of an internal
standard and liquid-liquid extraction with 2 mL tert-butylmethy-
lether (tBME) at basic pH, and reconstitution in 100 mL of mobile
phase to concentrate the sample. Reversed phase chromatographic
separation of the drugs and internal standard was performed on a
YMC, C8 analytical column under isocratic conditions. A binary
mobile phase was used consisting of 55% 20 mM sodium acetate
buffer (pH 4.88) and 45% acetonitrile. The UV detector set to
monitor the 212 nm wavelength provided adequate sensitivity
with minimal interference from endogenous matrix components.
Calibration curves are linear over the range of 50 to 20,000 ng/
mL. Inter- and intraday variability was less than 10%.
For MRV, a protein precipitation method using acetonitrile
(AcN) containing internal standard (MVC-d6) was employed to
extract the drug from macaques’ plasma. An aliquot of the
supernatant was further diluted with 0.5% tirfluoroacetic acid to
maintain signal intensity within the linear range of the instrument.
Reversed phase chromatographic separation was performed on an
XBridge C18 analytical column under isocratic conditions. A
binary mobile phase consisting of 0.1% formic acid in water and
0.1% formic acid in acetonitrile (72:28) was used and provided
adequate separation from other analytes. Detection and quanti-
tation was achieved by multiple reaction monitoring (MRM), and
MVC and internal standard were detected using the following
transitions for protonated molecular products [M+H]
+: m/z MVC
514.2.106.0; m/z MVC-d6 520.3.115.0. The assay has a
dynamic range of 5 to 5,000 ng/mL using 20 mL plasma.
For both DRV and MRV total drug concentrations were
measured (i.e free and protein bound).
Immunofluorescent staining and flow-cytometric analysis
Hematological analyses were performed by IDEXX (IDEXX
Preclinical Research, North Grafton, MA). For calculation of
absolute CD4
+ and CD8
+ T-cell numbers, whole blood was
stained with anti-CD3-fluorescein isothiocyanate (FITC)/anti-
CD4-phycoerythrin (PE)/anti-CD8-peridinin chlorophyll a pro-
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FITC/anti-CD20-PE, and red blood cells were lysed using lysing
reagent (Beckman Coulter, Inc., Fullerton, Calif.). Samples were
run on a FACSCanto II (BD Biosciences, San Jose, CA).
Staining for naı ¨ve (TN: CD28
+CD95
2), central and transitional
memory (TTCM/TM: CD28
+CD95
+), and effector memory (TEM:
CD28
2CD95
+) T-cells was performed on PBMCs isolated from
total blood of three rhesus macaques treated with H-iART. For
each animal, the blood was collected monthly from 0 to 4 months
from the addition of MRV to the drug regimen. The cells (3610
5
per sample) were surface stained by incubation with six
appropriately titrated monoclonal antibodies (mAbs) for 209 at
4uC, washed with PBS and resuspended in 1% paraformaldehyde
in PBS. The following mAbs were used: anti-CD3 (APC-Cy7),
anti-CD4 (Per-CP), anti-CD8 (Pe-Cy7), anti-CD20 (APC), anti-
CD28 (FITC) and anti-CD95 (PE). Six-parameter flow-cytometric
analysis was performed on a FACS Canto II instrument (BD
Biosciences) [7]. Staining for HLA DR
+ T-cells was performed
with the same procedure described above, but with the substitu-
tion of an anti-HLA-DR antibody (APC, clone G46-6) to the
aforementioned anti-CD20 antibody. The absolute numbers of
naı ¨ve (CD95
2CD28
+), long-lived (CD95
+CD28
+) and short-lived
(CD95
+CD28
2) memory CD4
+ T-cells and the numbers of HLA-
DR
+ cells were deduced from percentage values of parent cells.
SIVmac251 specific cellular immunity-ELISPOT assay
Specific immune responses were detected by measuring gamma
interferon (IFN-c) secretion of macaque PBMCs stimulated with a
SIVmac239 Gag peptide (15-mer, obtained through the AIDS
Research and Reference Reagent Program, National Institutes of
Health [NIH], catalogue no. 6204, peptide 64) in an enzyme-
linked immunospot (ELISPOT) assay. The assay was performed
with the ELISpotPRO for monkey interferon-c kit (Mabtech AB,
Nacka Strand, Sweden) according to the manufacturer’s instruc-
tions. Briefly, 1.5610
5 Ficoll isolated macaque PBMCs were
added to 96 well plates pre-coated with an anti-human/monkey
IFN-c antibody (MAb GZ-4). Cells were resuspended in RPMI
1640+10% FBS with 2 mg/mL of the peptide. After 48 hours
incubation at 37uC with 5% CO
2, the cells were rinsed from the
plates, and a biotinylated anti-human/monkey IFN-c antibody
(MAb 7-B6-1; Mabtech) was added to the wells. The plates were
then washed with PBS and incubated with the substrate solution
(BCIP/NBT-plus). Spots were counted by using an automated
reader (Immunospot Reader, CTL analyzers, LLC, Cleveland,
OH). Numbers of spot-forming cells (SFC)/10
6 cells for each set of
wells were averaged. A response was considered positive if the
number of SFC/10
6 cells was at least four times the background
value.
Statistical and biomathematical analyses
Data were analyzed using the software GraphPad Prism
5.00.288 (GraphPad Software, Inc., San Diego, CA). For
calculation of the EC50 and EC90 values, data were transformed
into percentage-of-inhibition values, plotted on x,y graphs, and
subjected to linear or non-linear regression, depending on the best-
fitting equation. Response to drugs in vivo was evaluated by
repeated-measures ANOVA, followed by an appropriate post-test
to analyze differences between time points. An appropriate
transformation was employed to restore normality, where neces-
sary. Logit analysis was adopted to investigate the influence of
variables on binary outcomes, using an online calculator (http://
statpages.org/logistic.html).
Trends in time were analyzed by regression analysis (GraphPad
Prism), using the most appropriate equations. Akaike’s information
criteria (AICc) were used to select the model that was most likely to
have generated the data and to compare the differences between
equation parameters.
The inter-assay variability of quantitative real time PCR was
estimated as an average of the coefficients of variation (CV) of
matched measurements in two assays conducted on different
Table 1. Ultrasensitive viral load measurements.
Macaque Time (in days) Viral RNA (copies/mL) Spike copies original count (RNA copies/mL)
P157 204 and 239 (see Fig. 2) ,3 * 7008
P185 204 and 239 (see Fig. 2) ,3 * 10822
P188 204 and 239 (see Fig. 2) ,3 * 8194
P177 312 and 347 (see Fig. 8) ,3 * 7692
1591 and 599 (see Fig. 8) ,3 ** 6062
1654 and 658 (see Fig. 8) ,3 ** 9060
P252 1215 and 365 (see Fig. 8) ,3 ** 6201
4416 238 and 272 (see Fig. 4) ,3 * 8276
BD12 98 and 105 (see Fig. 4) ,3 ** 9319
BD53 98 and 105 (see Fig. 4) ,3 ** 8494
BD64 400 and 407 (see Fig. 4) ,3 * 18997
BD69 381 and 388 (see Fig. 4) 27 * 8900
429 and 437 (see Fig. 4) ,4 (less plasma) ** 5569
451 and 458 (see Fig. 4) ,3 *** 20
Shown are the real time PCR viral RNA measurements of pooled plasma samples (two pooled samples per measurement; total plasma volume 6 mL; detection limit=3
RNA copies/mL). The time points selected for the analyses are shown as days from the zero point adopted in figures 2, 4 and 8. In these time points, the macaques were
under H-iART (unmarked), or off-treatment after therapy suspension (marked with ‘‘1’’). As a control of the assay variability and to exclude PCR inhibition, spiked RNA
measurements for each plasma sample are shown. The RNA copy numbers (in copies/mL) used for the spiked measurements were: * 8686; ** 8605; *** 34. The low copy
number spike was chosen to double-check the absence of low-level viremia in macaque BD69 that was the only one showing detectable viral RNA during the first PCR
run.
doi:10.1371/journal.ppat.1002774.t001
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coefficient of variation of multiple replicates (at least five) within
the same assay.
Numerical simulations were performed with the ordinary
differential equations solver ODEPACK of the Scilab 5.3.3
software (http://www.scilab.org/). The solver is based on finite
difference methods for non-stiff problems, but it dynamically
monitors the data in order to decide whether the stiffness of the
problem requires a Backward Differentiation Formula method.
The values of the discrete five-dimensional vector function of the
solution were computed every 0.01 days. Details on mathematical
modeling are given in Text S1.
Results
SIVmac251 is susceptible to darunavir (DRV) and
maraviroc (MRV)
The first part of this study was aimed at obtaining long-term
viral suppression in a group of macaques (n=4) in order to
develop a suitable platform for testing experimental eradication
strategies. We first analyzed the susceptibility of SIVmac251 to the
protease inhibitor darunavir (DRV) and the CCR5 blocker
maraviroc (MRV) in order to expand the arsenal of antiretroviral
options available for the macaque AIDS model. DRV was chosen
because of its well documented ability to inhibit several drug-
resistant HIV-1 isolates as well as HIV-2, a virus closely related to
SIVmac251 [1,14,15]. Moreover, the choice of this drug was
supported by preliminary bioinformatic and molecular modeling
analyses showing the potential interactions of DRV with the
SIVmac251 protease [Text S2 and Fig. S2]. MRV, a CCR5
antagonist, was chosen on the basis of the important role of CCR5
as a SIVmac251 co-receptor [16] and due to the antilentiviral
activity previously demonstrated by one experimental CCR5
blocker in macaques [17]. Moreover, retrospective analysis of one
previous in-vivo experiment supported the anti-SIVmac251 effect
of this drug [Text S3 and Fig. S3]. Results from tissue culture
experiments showed that both DRV and MRV inhibited
SIVmac251 replication in the nanomolar range, with EC50 values
well below the trough concentrations detected in macaques treated
with these drugs and described below in the text. (Fig. 1).
DRV improves the virological response of SIVmac251-
infected macaques to ART
A group of macaques [n=4] displaying signs of immune
deterioration (eighteen months post-inoculation) was treated with
a regimen of tenofovir, emtricitabine and raltegravir (Fig. 2).
These macaques were derived from viral titration experiments and
selected among those maintaining stable plasma viral loads
(Fig. 2A). The selected animals displayed viral load set points
between 10
3 and 10
5 viral RNA copies/mL. As our study was
Figure 1. SIVmac251 is susceptible to DRV and MRV. Comparison between effective drug concentrations required for 50% and 90% inhibition
of viral replication in vitro (respectively, EC50 and EC90) and the in vivo total levels (i.e. free and protein bound) of DRV and MRV in the plasma of six
animals treated with H-iART. All values are displayed as mean + SEM.
doi:10.1371/journal.ppat.1002774.g001
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HIV-1-infected individuals under ART, such baseline values were
chosen in order to reflect the average viral loads at which
treatment is started in humans. The CD4 counts displayed by the
macaques enrolled in this ‘‘pilot’’ study were significantly lower
than values observed in uninfected controls (Fig. S4), suggesting
that they were unlikely to be long-term non-progressors or e ´lite
controllers.
The three-drug regimen proved insufficient to maintain control
of viral load in three of the four animals treated (Fig. 2A). DRV
(375 mg bid), boosted with ritonavir (50 mg bid), henceforth
referred to as DRV/r, was added to the treatment in an attempt to
obtain a more stable control of viral load. DRV/r significantly
improved control of viral load, inasmuch as viral RNA in plasma
was maintained at a significantly lower level as compared to the
pre-therapy values (Fig. 2A). No similarly decreasing trend of viral
load was observed in an untreated control group of macaques
[n=2] showing non-significant differences in baseline viral loads
as compared to the treatment group (two tailed t-test: P=0.803;
Fig. 2A). We conclude that the iART regimen adopted improves
control of viral load in SIVmac251-infected macaques.
A H-iART regimen induces a prolonged control of
residual viremia
To increase the chances for long-term control of SIVmac251
replication, we explored the in-vivo efficacy of the CCR5 inhibitor
MRV. This drug (100 mg BID) was eventually added to the drug
cocktail in the aforementioned group of macaques (Fig. 2). After
MRV was started, all macaques stably maintained viral loads
below the limit of detection of the assay (i.e. 40 copies RNA/mL;
Fig. 2A). There were also significant increases in the absolute
numbers of CD4
+ T-lymphocytes (Fig. 2B). Henceforth, this
multidrug combination will be referred to as highly intensified
ART (H-iART).
MRV exerts antiretroviral effects in vivo
In order to further support the contribution of MRV to the
antiretroviral effects observed, we treated two macaques with
MRV (ritonavir boosted, MRV/r) in monotherapy (Fig. 3). In line
with its CCR5-blocking ability, MRV decreased the viral loads in
two drug-naı ¨ve macaques with dynamics similar to those
previously shown by an investigational CCR5 blocker [17]. When
the other H-iART drugs were added to MRV, a quick abatement
Figure 2. Viro-immunological control of antiretrovirally treated macaques chronically infected with SIVmac251. Panel A: Plasma viral
loads. Panel B: CD4 counts. The sequential treatments are represented by the colored areas. Asterisks represent the significant differences from
baseline values (respectively * P,0.05; ** P,0.01; *** P,0.001), as calculated by Bonferroni’s test. The values corresponding to the different macaques,
whose denominations are given in the legends, are shown by the different symbols and connecting lines. As a comparison, panel A shows the viral
loads dynamics of two untreated macaques (olive).
doi:10.1371/journal.ppat.1002774.g002
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demonstrated (Fig. 3).
H-iART suppresses viremia in a broad range of viremic
conditions
Prior to treatment with antiretrovirals, approximately one third
of the experimental infections of macaques with SIVmac251
results in viral set points comparable to those displayed by the
macaques described in the previous paragraphs (Fig. S5). To check
whether H-iART might reproducibly control viral replication in
SIVmac251 infected macaques characterized by higher viral
loads, five animals with viral set points ranging from 10
3 to 10
7
viral RNA copies/mL of plasma were treated with H-iART, and
the viral decay dynamics were compared with those of macaques
treated with iART. Results clearly showed that H-iART induced a
significantly more rapid decay in viral load than did iART
(Fig. 4A). In line with the efficacy of H-iART, CD4
+ T-cells
increased in all study macaques (Fig. S6). We conclude that MRV-
containing H-iART is superior to iART in abating viremia load in
a group of macaques with a wide array of baseline viral loads.
The extent of suppression of viral replication is
dependent on baseline viral loads and drug dosage in H-
iART-treated macaques
We then analyzed the viral load decay dynamics in macaques
treated with H-iART ab-initio. SIVmac251-infected macaques
responded to administration of H-iART with a two phase
exponential decay, as described in humans treated with suppres-
sive ART [18] (Fig. 4). Similarly to the average treatment
outcomes in humans [19], the level of viral load suppression
depended on the baseline viral loads, with macaques starting from
higher viral loads showing viral blips or residual, though markedly
decreased (.3 Logs), viral replication (Fig. 4D–F).
We increased the DRV and MRV dosage in macaques 4887,
BD64 and BD69, i.e. those starting from higher baseline viral loads
(.10
5) and showing incomplete control of viral replication or
major blips. Results showed that the improved drug regimen led to
viral loads consistently below the assay detection limit in animals
BD64 and BD69 (Fig. 4D,E). The increased drug dosage was also
able to decrease the amplitude of the remaining sporadic blips
(Fig. 4E). The resulting blips were lower than 10
3 copies of viral
RNA/mL, thus mimicking those observed in humans under ART
Figure 3. Ritonavir-boosted MRV (MRV/r) is able to decrease viremia in vivo. Panel A: Viral load measurements after infection and during
treatment with MRV/r (light yellow) and H-iART (light purple). Panel B (detail): Viral loads during MRV/r monotherapy in comparison to viral loads of
untreated controls.
doi:10.1371/journal.ppat.1002774.g003
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viremic episode. Analysis of the cerebrospinal fluid (CSF) of this
animal showed a viral load approximately one order of magnitude
higher than that in plasma, while CSF samples were below the
assay detection limit (i.e. 40 copies/mL) in the macaques showing
stable control of viral replication (data not shown). This evidence
suggested that the central nervous system (CNS) was a likely major
source for the rebounding virus in macaque 4887. According to
previously published studies: 1) virus levels in the CSF during the
advanced stages of the disease are mostly due to CNS sources [21],
and 2) the protease inhibitors (i.e., the only drug class in our
cocktail acting at a post-translational level, and hence on
chronically infected cells) are extruded from the CNS by P-
glycoprotein (P-gp) molecules in the blood-brain barrier [22]. We
thus intensified the P-gp blockade by increasing, from 50 to
100 mg bid, the dosage of ritonavir, which is a well-known P-gp
inhibitor [23]. The viral load decreased in both plasma and CSF,
with a more rapid decay kinetic in plasma, in which viral RNA
eventually fell to levels below the assay detection limit (Fig. 4F).
This result is in good agreement with the hypothesis of the CNS as
a major source for the rebounding virus.
We conclude that macaques starting from high viral loads
respond to H-iART similarly to HIV-infected humans and that
viral loads can be abated to levels below the assay detection limit
by adjusting the drug dosages and boosting procedures.
A highly sensitive viral load detection assay shows
profound suppression of viral replication by H-iART
To check the presence of low-level viremia in SIVmac251-
infected macaques under H-iART, we lowered the detection limit
to 3 copies of viral RNA/mL and re-measured viral loads in some
selected pooled serum samples. We found no evidence for low-
level viral replication in plasma of all of the macaques tested
(Table 1). Of note, viral RNA was below the assay detection limit
in the plasma samples taken from macaque 4887 before its last
viremic episode, supporting the hypothesis that H-iART was able
to completely control viral replication in the periphery, despite the
presence of a major CNS reservoir (Fig. 4F). Analyses conducted
on lymph node biopsies (inguinal) showed that four out of six
macaques analyzed had levels of cell-associated RNA below the
limit of detection of the assay (i.e. 2 copies/5*10
5 cells/mL)
(Table 2). The presence of cell-associated RNA in lymph nodes
was independent of baseline viremia at treatment initiation (Logit
analysis P=0.801), thus supporting the idea that the suppressive
efficacy of H-iART is not confined only to those macaques starting
from moderate viral loads. In addition, cell associated RNA
measured in samples taken from rectal biopsies was below the
assay detection limit in all animals analyzed, supporting the idea of
full suppression of peripheral viral replication (Table 2). This was
rather surprising, because other antiretroviral regimens adopted in
macaques proved unable to completely control viral RNA in
anatomical sanctuaries [3,24].
H-iART impacts on viral DNA in PBMCs, lymph nodes and
rectum
In the pilot study presented above, we unexpectedly found that
H-iART profoundly impacted on viral DNA. First, there was a
late viral DNA decay to levels below the assay detection limit
which was associated with the addition of MRV to the drug
cocktail (Fig. 5A). In addition, the CD4/CD8 ratio, the decrease of
which is a marker of the viral reservoir and/or ongoing viral
replication [7,8], significantly increased during treatment (Fig. 5B).
Of note, viral DNA in PBMCs also fell below the assay detection
limit in all macaques included in the group treated with H-iART
ab-initio (median treatment duration=125 days, range from 45 to
174 days), i.e. no viral DNA copies were detectable in six out of six
repeats with a threshold sensitivity of 2 copies/5*10
5 cells.
Figure 4. Viral load decay dynamics under H-iART treatment. Panel A: Comparison (two tailed t-test) of the antiretroviral efficacy of H-iART
and iART. Viral loads are the mean values from 5 animals (H-iART) or 4 animals (iART). Two of the animals treated with iART are historical controls (for
more detail see Table S1). The P-value was calculated by Aikaike’s information criteria (AIC) for comparison of curves. Panels B, C, D, E, F: Nonlinear
regression analysis (two phase decay) of viral load measurements during time. For macaque 4887, viral RNA levels in cerebrospinal fluid (CSF) are also
shown (in magenta).
doi:10.1371/journal.ppat.1002774.g004
Table 2. Cell associated RNA and DNA in lymph nodes and rectum.
Macaque Time (days) RNA DNA
Lymph Node (inguinal) Rectum Lymp Node (inguinal) Rectum
P157 289 (see Fig. 2) ,2 ,2 ,2 ,2
P177 289 (see Fig. 2) ,2 ,2 ,2 ,2
P185 289 (see Fig. 2) ,2 ,2 ,2 ,2
P188 289 (see Fig. 2) N/A ,2N / A ,2
BD12 140 (see Fig. 3) N/A ,2N / A ,2
4416 315 (see Fig. 4) N/A ,2N / A ,2
BD53 140 (see Fig. 3) N/A ,2N / A ,2
BD64 484 (see Fig. 4) 136 ,2 ,2 ,2
BD69 472 (see Fig. 4) 11 ,27 ,2
4887 484 (see Fig. 4) ,2 ,26 ,2
The limit of detection for both RNA and DNA assays is 2 copies/5*10
5 cells. Each assay was conducted in triplicate. The time points selected for the analyses are shown
as days from the zero point adopted in figures 2, 3 and 4.
doi:10.1371/journal.ppat.1002774.t002
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rectal tissue biopsies (detection limit: 2 copies/5*10
5 cells, three
repeats per sample) in all the macaques of the pilot study tested
(Table 2). Lymph node viral DNA was also below the assay
detection limit in one of three macaques from those treated with
H-iART ab-initio, while viral DNA was below the limit of detection
in rectal biopsies of all the macaques of the same group (Table 2).
The results were further validated by excluding the presence of
PCR inhibitors using spiked DNA for selected samples (Table S2).
Viral DNA decay dynamics during H-iART
The dynamics of the viral DNA decay during H-iART were
studied in those animals to which all H-iART drugs were
administered simultaneously and for which viral DNA measure-
ments were available.
The levels of viral DNA in PBMCs during time were consistent
with a three-phase decay, with the first two phases paralleling the
two-phase decay of viremia, and a third, slower phase occurring
after viremia had fallen to levels below the assay detection limit
(Fig. 5C). This last phase of the viral decay has been ascribed to
the latently infected T-cell numbers [18]. This result was
noteworthy, because no such decreasing trends in viral DNA
had been observed in animals treated with iART (i.e. without
MRV) [7].
H-iART impacts on the memory T-cell pool
In line with the reportedly stimulating effect of the major CCR5
ligand RANTES on T-cell proliferation [25] some studies
suggested that MRV, by acting as an antagonist of this cytokine,
might alter the T-cell dynamics in vivo [26]. To study these
phenomena, the CD4
+ T-cell subpopulations were analyzed by
six-color flow-cytometry at different time points following addition
of MRV to the therapeutic regimen (Fig. 6). To avoid biasing the
result with the possible effects of a detectable viral load on the T-
cell subpopulations, these tests were conducted on PBMCs from
macaques P157, P185 and P188 which already displayed a viral
Figure 5. H-iART decreases viral DNA in PBMCs and increases the CD4/CD8 ratio. Panel A: Viral DNA in PBMCs. Panel B: CD4/CD8 ratios.
Both panels show the results from macaques enrolled in the pilot study. The sequential treatments are represented by the colored areas. In panel A,
asterisks mark the significant differences from baseline values (P,0.05), as detected by Bonferroni’s test. Panel C: Three-phase decay dynamics of
total viral DNA of three macaques (BD69, 4416, P255) to which all H-iART drugs were administered simultaneously and for which viral DNA values
from treatment initiation were available. Each time point represents average values (6 SEM).
doi:10.1371/journal.ppat.1002774.g005
Figure 6. T-cell subpopulation dynamics during H-iART. Panel A: CD4
+ central and transitional memory T-cells (TCM/TTM) Panel B: CD4
+ effector
memory T-cells (TEM). Panel C: CD4
+ naı ¨ve T-cells (TN). Panel D: HLA-DR
+ T-cell subsets. In panels A–C, individual data points are presented for each
animal. The significantly decreasing trends are shown by the solid regression lines. Dashed lines refer to non significant trends (P.0.05). In panel D,
data are presented as means 6 SEM from three animals and significantly decreasing trends are shown by the asterisks.
doi:10.1371/journal.ppat.1002774.g006
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Results showed that H-iART decreased the memory CD4
+ T-cell
numbers over time (Fig. 6A,B), while it carried out no significant
effect on the naı ¨ve T-cell subpopulation (Fig. 6C). This result is in
accordance with the in-vitro inhibitory effect of MRV on the
proliferation of sorted memory T-cell subpopulations (Fig. S7).
MRV significantly decreased the numbers of activated (HLA-
DR
+) CD4
+ TEM cells (Fig. 6D). This effect is in line with
decreased levels of immune activation already observed in humans
treated with this drug [26,27]. In conclusion, MRV decreased the
number of memory T-cells as well as TEM cell-activation. Since
these two parameters are linked to the magnitude of the viral
reservoir and ongoing viral replication [9,28], this effect is in good
agreement with the aforementioned three-phase decay of viral
DNA induced by MRV (Fig. 5C).
MRV impacts on the viral set point following therapy
suspension
The results so far obtained were in line with a recently issued
report which suggested that MRV decreased the magnitude of the
viral reservoir in HIV-1-infected individuals [26]. This study,
which was unable to provide conclusive evidence, did not show an
impact of MRV on the viral set point following therapy
suspension, a parameter stringently associated with the extent of
the viral reservoir [7,29,30]. To test this hypothesis, we analyzed
the difference in the pre and post-therapy viral set points in those
macaques from our cohort that had received MRV and that had
undergone therapy suspension (for treatment details see Figs. 2, 4
and Text S3). Results show that treatment with MRV is associated
with a reduction of the viral set point post-therapy (Fig. 7A), and
that the extent in the viral set point decrease depends on the total
exposure to the drug (Fig. 7B). These results are suggestive of an
independent effect of MRV on the viral set point following therapy
suspension and add credit to the hypothesis that MRV may
contribute to an anti-reservoir effect of H-iART.
H-iART improves the spontaneous control of viral load
following a previous anti-reservoir strategy
Finally, given the aforementioned effects of H-iART, we tested
whether this therapeutic regimen might be adopted to improve the
effect of a previous anti-reservoir strategy based on the anti-
memory drug auranofin in combination with antiretrovirals [7].
Upon interruption of this anti-reservoir treatment, SIVmac251-
infected macaques experience an acute infection-like condition, i.e.
an initial viral load peak followed by rapid containment of viral
load [7]. The peak, which is rapidly reached upon virus re-
appearance in plasma, is associated with the reconstitution of the
viral reservoir, as shown by the previously published independent
association between the area under the curve (AUC) describing the
initial peak of viral load and the eventual viral load set point ([7]
see also Fig. 8A). From this association, it follows that decreasing
the AUC at peak artificially through a cycle of H-iART should
limit the reconstitution of the viral reservoir and may result in
spontaneous control of viral load following H-iART suspension.
The experiment was attempted in two macaques. A first
macaque (P252) was treated with a one-month cycle of H-iART at
viral load rebound, after the suspension of the aforementioned
auranofin/antiretroviral regimen. Another macaque (P177) was
treated with auranofin in addition to H-iART as a follow-up of the
treatment presented in the pilot study. Eventually, following
therapy suspension, P177 was subjected to a short H-iART cycle
at viral rebound, similar to that administered to P252. In both
cases, the short H-iART cycle promptly abated viral load to levels
below the assay detection limit, thus efficiently decreasing the
initial AUC (Fig. 8 A–C).
Figure 7. MRV decreases the post-therapy viral load set point. Panel A: Pre and post therapy Log10 viral load set points of four SIVmac251
infected macaques treated with MRV-containing therapies. The P-value shown is the result of paired t-test analysis. Panel B: Correlation between the
Log10 D viral load set point (i.e. the difference between pre and post therapy viral load set points) and time of exposure to MRV. Correlation was
investigated using Pearson’s coefficients. The treatment of macaques 4388 and 4398 prior to therapy suspension is shown in Figure S7 and Text S2.
doi:10.1371/journal.ppat.1002774.g007
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the short cycle of H-iART was suspended, in line with the
expected values calculated on the basis of our AUC/viral set point
correlation curve (Fig. 8A). Both macaques periodically displayed
viral load peaks that subsequently decreased to low-level viremia
(,500 copies of viral RNA/mL) or to levels below the assay
detection limits. The CD4 slope was non-significant during the
follow-up period (P=0.7079 for P252 and P=0.2319 for P177;
Fig. 8D,E), in line with the previous observation that the CD4
slope following therapy suspension identifies the impact of a
treatment on the viral reservoir [7]. Conversely, CD4 counts had
shown significantly decreasing trends in both macaques before all
treatments were started (P,0.0001 for P252 and P=0.0039 for
P177; Fig. 8D,E), thus supporting the concept that the therapies
adopted significantly impacted on the natural course of the
disease.
Consistently with its exceptional reduction of the AUC at peak,
macaque P177 showed a remarkable degree of spontaneous
control of viral load during six months of follow-up, which was not
yet considerable as, but seemingly close to a drug-free remission of
the disease (Fig. 8C). In this macaque, viral load was maintained at
levels below the assay detection limit during the periods between
peaks (detection limit: 40 RNA copies/mL) and, when the RNA
detection limit was further lowered to 3 copies/mL, no evidence of
residual viremia was found (see Table 1). This control of viral
replication could hardly be ascribed to cell-mediated responses, in
that a moderate increase in the number of IFN-c positive spots
could be detected only at viral rebound but not during the viral set
point (Fig. S8), thus suggesting that H-iART induced a true
containment of the viral reservoir reconstitution, similarly to other
experimental strategies restricting the formation of the viral
reservoir during acute infection [29,30,31]. We conclude that a
short course of H-iART, in line with the highly suppressive effect
of this therapeutic regimen on SIVmac251, may prevent the viral
reservoir reconstitution following suspension of a previous anti-
reservoir therapy and result in a drug-free spontaneous control of
viral load.
Discussion
Some investigators recently questioned the robustness of
primate models, citing the difficulty of obtaining, with the cross-
active drug options available, full viral suppression in sanctuaries
and viral loads below the assay detection limits for prolonged
periods [32,33]. The results reported in the present article do not
support this argument.
Figure 8. A short cycle of H-iART at viral rebound after structured treatment interruption improves the effects of auranofin-based
anti-reservoir therapies on the eventual viral load set point. Panel A: Correlation between the area under the viral load curve at peak (AUC)
following viral rebound and the eventual viral load set point. Panels B,C: Viral loads from infection of macaques subjected to the combined
antireservoir/antiretroviral treatment protocol (see main text). The red bars mark the viral set points (calculated as the mean of the available Log10
viral load measurements). Panels D,E: CD4 counts. The values before and after the treatment periods are shown by the individual data points, and
trends are described by the regression lines (solid: significant slopes; dashed: non significant slopes).
doi:10.1371/journal.ppat.1002774.g008
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suppression in humans, we checked viral loads in plasma for
prolonged periods and analyzed the presence of viral nucleic acids
in anatomical sanctuaries. The level of abatement of viral nucleic
acids that we found in the present study in peripheral blood and
anatomical sanctuaries of the majority of the macaques tested
provide the maximum degree of viral suppression so far observed
in antiretroviral treated primates. The level of reproducibility of
these results is shown by the fact that they were obtained in a
heterogeneous group of macaques, likely mirroring a wide number
of possible disease conditions in humans. This is the first report, to
our knowledge, of a therapy capable of stably controlling viral
replication to levels below the assay detection limits also in
macaques in the advanced stage of the disease, since the studies so
far published have been able to report control of SIV replication
only during acute infection [12] or in the early chronic phase of
the disease [3–6]. Apart from mimicking the clinical conditions of
a significant portion of HIV-infected individuals who are
diagnosed in the chronic or pre-AIDS stages of the disease, this
‘late’ treatment allows excluding those macaques able to sponta-
neously control the infection, a phenomenon which usually occurs
soon after the acute infection phase [34]. For the macaques
enrolled in this study, the average plasma viral load at the time of
therapy initiation was of 4.861.1 Log10 RNA copies/mL (mean 6
SD). This value is lower than those reported in some articles
during chronic SIVmac infection of macaques [35,36], but similar
to those published in other articles [37,38]. As in this study we
have not included macaques with viral loads during chronic
infection higher than 6.8 Log10 RNA copies/mL or with the rapid
progressor phenotype, the effect of our H-iART regimen on
this more aggressive course of SIV infections remain to be
ascertained.
Of note, persistence of the virus at low level in the lymph nodes
of a minority of H-iART treated macaques provides another
similarity of our macaque model with clinical conditions observed
in humans infected with HIV-1, as this anatomical sanctuary has
recently been shown to be a major site for ongoing viral replication
in humans [39]. Studies of drug penetration in this anatomical
Figure 9. Numerical simulations of the Rong and Perelson model with programmed expansion and contraction of the viral
reservoir. Panel A: Simulation of the viral load and viral reservoir dynamics in a human model. The 300 days simulation is based on the five
differential equations model (4) in [40], where burst size is assumed to be 2000 RNA copies/day. The peaks in the viral load (violet) correspond to the
periods of activation of latently infected CD4
+ T-cells. Proliferation rate and drug efficacy are assumed to be respectively 1.4 and 0.85. For starting
data see Table S3. Panels B–D: Simulation of the viral load and viral reservoir dynamics infection in a macaque model. According to [41] burst size is
assumed to be 55000 RNA copies/day, which determines higher peaks in the viral load than in the previous human model. Panel B: proliferation
rate=1.4, drug efficacy=0.95. Panel C: proliferation rate=1.4, drug efficacy=0.99. Panel D: proliferation rate=0.945, drug efficacy=0.99. The
activation function adopted to simulate lymphocyte encounter with antigens is illustrated in Fig. S9 (for further detail, see Text S1).
doi:10.1371/journal.ppat.1002774.g009
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macaques and humans.
2) As in any well respected science, the results are in good
agreement with mathematical models (Fig. 9), and are mathemat-
ically predictable (as an example, see Fig. 8A). In this regard,
important insight into the necessity for a multidrug regimen to
control viral loads in macaques can be derived from a
mathematical model developed by Rong and Perelson [40] and
based on experimental observations [8]. This model suggests that a
superior drug efficacy is required in simian AIDS to control viral
replication (Fig. 9) because of the viral burst size, (i.e. the average
number of virions produced by a single productively infected cell
in a day). The viral burst size was shown to be higher in SIV
infection as compared to HIV-1 infection [41], where a lower drug
efficacy is expected to be sufficient to maintain viral control
(Fig. 9A–C). Also a drug acting on the proliferation rate of
activated T-cells, such as MRV (which antagonizes the prolifer-
ative effect of RANTES, see ref 25 and Fig. S7), appears to be
important for containment of the viral blips (Fig. 9D). These
simulations also show that the decreased proliferation rates may
impact on the viral reservoir size (half-life: <200 days, see Text S4,
S3, S2, S1 and Fig. 9D), which shows a half-life of the same order
of magnitude as that calculated by analyzing the dynamics of the
viral DNA decay during H-iART (Fig. 5).
3) According to the idea that a good animal model should
represent a vanguard for future treatments to be tested in humans,
our quest for increased drug efficacy in the macaque AIDS model
allowed identifying unexpected benefits of H-iART on the
immune system. Apart from the possible impact of H-iART on
the viral reservoir (a concept supported by recent data in humans
[42]), reduction by MRV of the memory T-cell subpopulation
may restrict one major source for viral spread and ongoing viral
replication. A decrease in the memory T-cell size is a logical
expectation of the anti-proliferative effect exerted by MRV
through CCR5 inhibition (Fig. S7), as antigen-driven proliferation
contributes to maintenance of the size of this T-cell subpopulation
[8]. It is well known that memory T-cells are a preferential target
of HIV-1 replication [43], and that their decrease may affect the
overall viral dynamics in vivo. In this regard, the MRV-induced
decrease in the memory T-cell size is not only unlikely to be
dangerous but, rather, likely to be beneficial. This hypothesis is
supported by results showing that the pool of TCM cells is a
correlate of anergy towards the viral antigens in Macaca mulatta but
not in Cercocebus atys, which is naturally resistant to CD4+ T-cell
loss and full-blown AIDS [44]. In addition, the results obtained
with the present macaque model suggest that a short cycle of H-
iART could be used for improving the efficacy of our previous
anti-reservoir treatment based on auranofin and strengthen the
idea that an arrest in disease progression may be obtained during
the chronic phase of the disease. Although the data on the
combined effect of the two subsequent treatment cycles are
derived from a limited number of macaques, the result obtained is
corroborated by the fact that no similar trend was observed in the
same animals prior to starting therapy [5,7] or in historical
controls that had not received H-iART at rebound [7]. Of note,
although certain major histocompatibility complex (MHC) class I
alleles, including Mamu-A*01 and Mamu-B17* are associated
with slow disease progression in SIV infected macaques [45,46],
independently, the presence of these alleles is not predictive for
disease outcome [47], and none of our macaques presented the
protective alleles in association (Table S1). Instead, P177, which,
following our therapies, remarkably controlled viral load, present-
ed the HLA Mamu-B*01 allele, that is associated with aggressive
simian lentivirus infection [48]. In line with this genotype, P177
showed a significant immune deterioration before our treatments
were initiated (Fig. 8C).
Finally, recent analyses [reviewed in 49] re-evaluated the
necessity of wide numbers of subjects as a support for
breakthrough findings, such as, in this case, the obtainment of a
condition close to a persistent suppression of viremia in the
absence of ART.
If the results of the present study should prove reproducible in
humans, H-iART could represent a useful tool for improving the
viro-immunological conditions of HIV-infected individuals and a
useful addition to experimental anti-reservoir strategies.
Supporting Information
Figure S1 Variability of the quantitative real-time RT-
PCR assay for measurement of viral RNA. Panel A:
Standard curves run on three different occasions. Panel B:
Coefficients of variation at different starting RNA concentrations.
The coefficients of variation were calculated as the standard
deviation of each group of values (starting from the same RNA
concentration) divided by the mean value and multiplied by 100.
Lack of concentration-dependence shows that the variability at the
different concentrations is due to random fluctuations rather than
to loss of sensitivity at the extremes of the curve.
(TIF)
Figure S2 Structural analysis of SIVmac251 suscepti-
bility to darunavir. Panel A: Sequence alignment of the
protease of HIV-1 subtype B [PDB: 2HS1,V32I Mutant], HIV-2
[PDB: 3ECG], and SIVmac251 [PDB: 2SAM]. The sequence
alignment is based on a structural alignment performed using the
VAST algorithm. Regions showing significant structural alignment
are presented in blue, with the highly conserved residues shown in
red. The mutations found in HIV-1 infected individuals failing
DRV-based drug regimens are highlighted above the alignments
(the green arrows indicate the primary resistance mutations; black
arrows indicate secondary resistance mutations). Panel B:
Comparison between the DRV/HIV-1-protease experimental
model (green sticks) and our DRV/SIVmac251-protease theoret-
ical model (cyan transparent sticks). Yellow dashes depict the
hydrogen bonds and the red sphere indicates the position of the
structural water molecule involved in drug-protein interactions.
Amino acids and DRV are represented in CPK. The methodology
adopted for the molecular modeling, is described in detail in the
Text S1.
(TIF)
Figure S3 Viral loads of SIVmac251-infected macaques
before and during treatment with maraviroc, tenofovir
and emtricitabine. Asterisks show the significant differences
between values at start of follow-up and during treatment
[P,0.05, Bonferroni’s post test following significant (P,0.05)
repeated-measures ANOVA].
(TIF)
Figure S4 CD4
+ T-cell counts of six uninfected and four
SIVmac251 infected macaques. Individual data points, as
well as means (6 SEM), are shown for each group.
(TIF)
Figure S5 Examples of SIVmac251 infection course in
rhesus macaques. Depicted is the progression of viremia in a
cohort of seven SIVmac251 infected rhesus macaques. In red are
the macaques displaying similar viral loads as those of the animals
enrolled in the pilot study (see text).
(TIF)
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+ T-cell
counts decreased by pathogenic SIVmac251 infection.
Five macaques are considered for which pre-infection and pre-
treatment CD4
+ T-cell counts were available. Values during H-
iART refer to a median period of 89 days (range: 83–89 days).
Data have been analyzed using one-way ANOVA followed by
Newmann-Keuls test.
(TIF)
Figure S7 Maraviroc decreases T-cell proliferation in
vitro. The percentage inhibition of proliferation induced by
0.1 mM MRV in CD4
+ T-cells activated with aCD3/aCD28 is
shown. Data are shown as mean + SEM and are derived from two
experiments. CM: central memory; TM: transitional memory;
EM: effector memory. P=0.0417; Friedman’s test.
(TIF)
Figure S8 ELISPOT analysis of the number of interfer-
on-c secreting cells/1.5 * 10
5 PBMCs. The analyses refers to
A: macaque P252 and B: macaque P177. The time points selected
are shown as days from the zero point adopted in figure 8 of the
main text.
(TIF)
Figure S9 Activation function. The step function f(t) which
determines the activation of resting latently infected CD4
+ T-cells.
Times between two activation periods follow a Poisson distribution
with a mean of 50 days. The length of activation periods follows a
uniform distribution over an interval of 4 to 6 days.
(TIF)
Table S1 Viro-immunological background and thera-
peutic regimens of the SIVmac251 infected macaques
employed in the study. MHC alleles analyzed are the
following: Mamu A*01; A*02; A*08; A*11; B*01; B*03; B*04;
B*08; B*17. The CD4 nadir is chosen as the lowest pre-therapy T-
CD4 count available. Therapeutic regimens described in the
present article are highlighted in violet.
(TIF)
Table S2 Validation of the real-time PCR assay for
SIVmac251 DNA quantification in PBMCs and lymph
node biopsies. The limit of detection of the assay is 2 copies/
5*10
5 cells. As a control of the assay variability and to exclude
PCR inhibition, spiked DNA measurements for each sample were
used.
(TIF)
Table S3 Starting data for the numerical simulations of
the viral load and reservoir dynamics.
(TIF)
Text S1 Mathematical modeling and numerical simu-
lations.
(DOCX)
Text S2 Bioinformatic analyses and molecular model-
ing studies.
(DOCX)
Text S3 Retrospective analysis of the response of SIV-
mac251 to maraviroc in vivo.
(DOCX)
Text S4 In vitro measurement of the effect of MRV on
T-cell proliferation.
(DOCX)
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